Introduction & Objective: Missing doses in people living with diabetes (PLWD) who use multiple daily insulin injections may lead to inadequate glycemic control. This real-world study assessed the probability of and influencing factors for missed bolus insulin injections in PLWD.
Methods: Data from 21 countries were collected from 22 964 adults with T1D or T2D using CGM and a smart pen (NovoPen 6 or NovoPen Echo Plus) to deliver bolus insulin (2 559 118 CGM and injection days [111 days/adult]). The daily probability of missing ≥ 1 bolus dose (no bolus dose within −15 to +60 mins from meal onset detected by the GRID algorithm) was estimated by a generalized linear mixed model based on logistic regression. Data upload frequency (pen to app) was used as a proxy for smart pen engagement.
Results: The mean probability of having a day with ≥ 1 missed bolus dose was 44.5% (95% CI: 44.1-45.0%), which decreased with increasing age (Figure A) and smart pen data upload frequency (not shown). The probability of having a day with ≥ 1 missed bolus dose was highest on Fridays and Saturdays (Figure B). On any given day, the probability of missing a bolus dose at breakfast, lunch, dinner or snack was 7.5%, 12.2%, 11.1% and 19.4%, respectively.
Conclusion: Bolus insulin adherence increased with age and smart pen engagement and decreased on weekends. Smart insulin pen data can provide novel insights into individuals’ real-world injection behaviors.
F. Ampudia Blasco: Advisory Panel; Novo Nordisk, Sanofi. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Roche Diagnostics, Bayer Inc. M.L. Jensen: Employee; Novo Nordisk. A. Kaas: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. N.N. Knudsen: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. R. Nishimura: Speaker's Bureau; Abbott. Advisory Panel; Abbott Japan Co., Ltd. Speaker's Bureau; Boehringer-Ingelheim, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Medtronic, Sanofi, Taiho Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Eli Lilly and Company, Novo Nordisk A/S. Consultant; Terumo Corporation.
Novo Nordisk A/S